Business
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
ABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of atopic dermatitis VANCOUVER,
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\nABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of atopic dermatitis\n\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, a next-generation investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications for other inflammatory and autoimmune conditions. ABCL575 targets OX40 ligand and has been engineered to support a dosing interval of once every six months, which is less frequent than current clinical-stage molecules.\n\n\nThe Phase 1 clinical trial of ABCL575 (NCT07108894) is a randomized, placebo-controlled, double-blind study to assess safety and tolerability in healthy participants following subcutaneous doses of ABCL575. Data from this study is expected in mid 2026.\n\n\nAbout ABCL575\n\n\nABCL575 is an Fc-silenced, half-life extended investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications for other inflammatory and autoimmune conditions. ABCL575 binds OX40 ligand (OX40L) to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In preclinical studies, ABCL575 shows potent inhibition of T cell-mediated inflammatory pathways, favorable safety profile, and an in vivo half-life that is expected to support less frequent dosing than current clinical-stage molecules.\n\n\nAbout AbCellera Biologics Inc.\n\n\nAbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com.\n\n\nAbCellera Forward-Looking Statements\n\n\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regardi...